Fig 2: DDX21 does not interact with SVA 2B and 3C protein. (A) HEK293T cells were cotransfected with HA-DDX21 and 2B-Flag. (B) HEK293T cells were cotransfected with HA-DDX21 and 3C-flag. Coimmunoprecipitation (Co-IP) was performed using agarose beads conjugated with anti-Flag mAb agarose beads. Precipitated proteins were analyzed by WB using antibodies against the Flag and HA.

Fig 3: (A, B) Correlation between DDX21 expression and cancer-associated fibroblast immune infiltration. EPIC, MCPCOUNTER, and TIDE algorithms were used to calculate the correlation between DDX21 expression and cancer-associated fibroblast immune infiltration in all tumor types in TCGA.

Fig 4: SVA degrades endogenous DDX21 during viral infection, and DDX21 is degraded by SVA 2B and 3C. (A) BHK-21 cells in 6-well plates were infected with SVA at a MOI of 0.1, cells were harvested at indicated times, and the expression level of endogenous DDX21 protein was analyzed by WB. (B) HEK293T cells in six-well plates were cotransfected with HA-DDX21 and Flag-VP1, VP2, VP3, 2B, 2C, 3A, 3C, or 3D, cells were harvested at 30 h, and the samples were analyzed by WB. (C, D) HEK293T cells were cotransfected with HA-DDX21 and different concentrations of Flag-2B or Flag-3C for 30 h. The cell lysates were analyzed by WB.

Fig 5: DDX21 expression profiles in human normal and cancer tissues. (A) Consensus DDX21 tissue expression based on datasets of HPA (Human Protein Atlas), GTEx, and FANTOM5 (Function ANnoTation Of the Mammalian genome). (B) Abundance of the DDX21 protein in human normal tissues. Representative IHC images of DDX21 expression between normal (left) and tumor (right) tissues. (C, D) Lung. (E) Endometrium. (F) Colon. (G) Breast. (H) Ovary. (I) Based on the CPTAC dataset, we also analyzed the abundance of DDX21 protein between normal tissues and primary breast cancer, ovarian cancer, colon cancer, clear cell RCC, UCEC, and LUAD tissues (***p < 0.001).